Quoin Pharmaceuticals hits interim Phase 2/3 endpoints for QRX003

Quoin Pharmaceuticals has reported positive interim data from its ongoing Phase 2/3 trial of QRX003 4% lotion in Netherton Syndrome, with four of the first six participants to complete the 12-week treatment period achieving the primary endpoint of a one-grade or greater improvement in Investigator Global Assessment (IGA). The result cleared the pre-specified alpha adjustment for interim analysis with a p-value of 0.0087 against a threshold of 0.0215.

The NASDAQ-listed company said the key secondary endpoint, a Global Impression of Change measure, also achieved statistical significance at week 12, with participants recording a mean change of -1.5 (SD 0.82) and a p-value of 0.007 against the same pre-specified alpha. A consistent pattern emerged across endpoints: the same four participants who met the IGA primary endpoint also recorded clinically meaningful improvements in the Ichthyosis Area and Severity Index, with severity reductions ranging from 31% to 87% from baseline.

Clinical readout details

All three participants who had moderate to severe pruritus at baseline achieved at least a three-grade improvement on the Worst Itch Numeric Rating Scale, with one individual recording a greater than six-grade improvement. The itch responder analysis returned a p-value of 0.0623, which did not meet the pre-specified alpha, though Quoin highlighted that this result was achieved in participants who had discontinued all concurrent topical and systemic therapies for the duration of the study.

No treatment-related serious adverse events were reported, and no clinically significant ECG, laboratory, or vital sign abnormalities were identified.

"These interim results provide further objective evidence that QRX003 has the potential to change the course of Netherton Syndrome," said Dr Michael Myers, chief executive and co-founder of Quoin Pharmaceuticals. He noted the consistency across two independent physician-assessed skin endpoints as support for the robustness of the findings.

Quoin expects to complete recruitment of all 20 participants by the end of 2026 and report topline data in the second quarter of 2027. The company has indicated it is considering an NDA filing in 2027, though no formal submission timeline has been confirmed.

Regulatory and competitive landscape

QRX003 carries FDA Orphan Drug, Rare Pediatric Disease, and Fast Track designations, as well as Orphan Drug Designation in the EU and Japan. There are currently no therapies specifically approved for Netherton Syndrome in the United States, meaning a successful NDA would position QRX003 as the first approved treatment for the condition, as the company claims. That first-mover status, combined with the rare paediatric disease voucher attached to the programme, represents a meaningful commercial incentive: priority review vouchers have traded at valuations above $100 million in recent years, providing a potential near-term asset even ahead of approval.

Netherton Syndrome is caused by mutations in the SPINK5 gene and is characterised by chronic skin barrier disruption and elevated serine protease activity. The rarity and severity of the condition, combined with the complete absence of approved therapies, has attracted growing preclinical interest from academic groups and a small number of university-spinout biotechs pursuing different mechanistic approaches. QRX003's lotion-based serine protease inhibitor mechanism is distinct from biologics targeting the IL-4/IL-13 or TSLP pathways that have been explored in adjacent inflammatory skin disorders, and it is unclear whether immunology-focused competitors will attempt to cross into this indication.

The interim dataset is small, and the wide confidence interval on the primary endpoint (22.28% to 95.67%) reflects the limited sample size. Investors and clinicians will look to the full 20-patient readout in mid-2027 for a more definitive view of the benefit-risk profile before drawing firm conclusions about QRX003's commercial prospects.